February is Age-Related Macular Degeneration (AMD) Awareness month

February is Age-Related Macular Degeneration (AMD) Awareness month and here at DocTrials, we have been committed to helping advance medicine's treatment of ophthalmic diseases. We are proud to have participated in a Phase III trial that led to the FDA-approved treatment for wet AMD that has been now dosed over 2 million times!

It is exciting to see how hard work from our team and our patients can lead to tangible advancements in the field of retina. #doctrials #clinicaltrials #research #ophthalmology #retina

www.vabysmo-hcp.com

Previous
Previous

Next
Next

Ocugen Doses First Patient in the ArMaDa Clinical Trial